Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins FDA Approval

Keytruda Qlex, an injectable version of Merck’s cancer immunotherapy, can be administered in minutes compared to the 30 minutes needed to dose the original infused formulation. The FDA approval is based on clinical trial results showing the injectable formulation was comparable to infused Keytruda. The post Merck’s Injectable Version of Blockbuster Cancer Drug Keytruda Wins…

Read More

Inequality aversion and option value

Many policymakers aim to reduce health disparities across groups. In fact, the distributional cost effectiveness analysis (DCEA) approach aims to incorporate treatment value based on the extent to which they reduce inequality. However, what types of inequality are we trying to reduce: ex-post or ex-ante? Ex post inequality means reducing inequality of outcomes at a…

Read More